In Brief: Once-Monthly Lecanemab (Leqembi) for Alzheimer's Disease

The amyloid beta-directed monoclonal antibody lecanemab-irmb (Leqembi – Eisai/Biogen)1 has now been approved by the FDA for once-monthly use for treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia. It was previously approved only for administration once every 2 weeks. Now, lecanemab can be given every 4 weeks after an 18-month initiation phase of biweekly administration.

Publication Details

Journal
˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Published
2025-04-03
DOI
https://doi.org/10.58347/tml.2025.1726f
Citations
1
Primary Topic
14-3-3 protein interactions
Type
article
Field-Weighted Citation Impact
0.81
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In Brief: Once-Monthly Lecanemab (Leqembi) for Alzheimer's Disease

1 citations
˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
14-3-3 protein interactions
0.81
article

In Brief: Once-Monthly Lecanemab (Leqembi) for Alzheimer's Disease

article en
1 citations

Abstract

The amyloid beta-directed monoclonal antibody lecanemab-irmb (Leqembi – Eisai/Biogen)1 has now been approved by the FDA for once-monthly use for treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia. It was previously approved only for administration once every 2 weeks. Now, lecanemab can be given every 4 weeks after an 18-month initiation phase of biweekly administration.

˜The œmedical letter on drugs and therapeutics/˜The œmedical letterVol. 67(1726)
Good health and well-being
Openalex Percentile: Top 29%
14-3-3 protein interactions
0.81
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

In Brief: Once-Monthly Lecanemab (Leqembi) for Alzheimer's Disease · ˜The œmedical letter on drugs and therapeutics/˜The œmedical letter (2025) | TGRS Research Map | TGRS